跳至主要内容
临床试验/NCT03489772
NCT03489772已完成1 期

A Randomized, Placebo-Controlled, Double-Blind Study of Escalating Single Doses of ITI-214 in Healthy Volunteers to Determine Central Nervous System Engagement, Safety and Tolerability

Intra-Cellular Therapies, Inc.1 个研究点 分布在 1 个国家目标入组 26 人开始时间: 2018年7月10日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
26
试验地点
1
主要终点
BOLD MRI signals in the anterior insula during the extinction phase of a Fear Conditioning task

研究概览

简要总结

This is a single site, randomized, double-blind, placebo-controlled, within-subjects study design in healthy volunteers. Escalating single doses of ITI-214 will be evaluated using functional magnetic resonance imaging (fMRI) to determine central nervous system engagement. Safety and tolerability also will be assessed.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Basic Science
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 45 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Healthy male or female, 18 - 45 years
  • Fluent and literate in English and able to provide written informed consent
  • BMI between 18.5 and 38.0 kg/m2 and minimum body weight of 50 kg

排除标准

  • Recent exposure to any investigational product
  • Previous exposure to relevant fMRI task(s)
  • Considered medically unsuitable for participation
  • Has any contraindication for BOLD fMRI

研究组 & 干预措施

1 mg ITI-214

Experimental

Single dose

干预措施: ITI-214 (Drug)

10 mg ITI-214

Experimental

Single dose

干预措施: ITI-214 (Drug)

Placebo

Placebo Comparator

Single dose

干预措施: Placebo (Drug)

结局指标

主要结局

BOLD MRI signals in the anterior insula during the extinction phase of a Fear Conditioning task

时间窗: 1-3 hours post-dose

Changes in brain activation

BOLD MRI signals in the inferior frontal gyrus during the Stop Signal Task

时间窗: 1-3 hours post-dose

Changes in brain activation

次要结局

  • BOLD fMRI signals elicited by the Stop versus Go signal(1-3 hours post-dose)
  • BOLD fMRI signals elicited by fear conditioning stimulus(1-3 hours post-dose)
  • Number of subjects with reported or observed treatment-related adverse events(0-5 hours post-dose)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验